Patents Examined by Satyendra Singh
  • Patent number: 8980254
    Abstract: Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: March 17, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventors: Matthew John Siegel, Bret Berner
  • Patent number: 8951782
    Abstract: An apparatus for separating cells using magnetic force includes: a separation channel portion including ferromagnetic particles, and provided with a flow path through which a cell fluid containing a plurality of cells having at least one of diamagnetic and paramagnetic properties; and a magnetic field controller that generates a magnetic field within the flow path so that the cells in the cell fluid flow within the flow path and are separated by height by a magnetic field. Accordingly, there are provided an apparatus for separating cells using magnetic force and a cell separation method using the same, by which cells can be easily separated using magnetic force.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: February 10, 2015
    Assignee: Korea Institute of Machinery & Materials
    Inventors: Sung Hwan Chang, Yeong-Eun Yoo, Doo-Sun Choi, Kyung-Hyun Whang
  • Patent number: 8940500
    Abstract: Methods are disclosed for the characterization of the stage of development or pathology of a tissue sample, and for identifying pluripotent metakaryotic stem cells, comprising detecting fluorescence of cells and syncytia in fixed samples treated with a non-fluorescent Schiff's base reagent in the absence of extraneous or exogenously added fluorescent dyes.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: January 27, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Elena V. Gostjeva, William G. Thilly
  • Patent number: 8936939
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: January 20, 2015
    Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Patent number: 8932587
    Abstract: This invention relates generally to a therapeutic use of alkaline phosphatase to reduce or inhibit toxic effects associated with a bacterial infection in a subject.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: January 13, 2015
    Assignee: The General Hospital Corporation
    Inventors: Richard A. Hodin, Madhu S. Malo
  • Patent number: 8822172
    Abstract: A method of measuring isolevuglandin and/or levuglandin adducts associated with oxidative injury in a subject includes obtaining a bodily sample from a subject suspected of including isolevuglandin and/or levuglandin phospholipid adducts, hydrolyzing isolevuglandin and/or levuglandin phospholipid adducts from the sample with an enzyme that forms isolevuglandin and/or levuglandin phospholipid derivatives, and determining the amount of isolevuglandin and/or levuglandin phospholipid derivatives by mass spectrometry.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: September 2, 2014
    Assignee: Case Western Reserve University
    Inventors: Robert Salomon, Wei Li
  • Patent number: 8809014
    Abstract: Method for assessing condition of skin and/or scalp by resulted color from the interaction of protein detecting composition with skin and/or scalp sample. Also disclosed is a method for comparing condition of different skin and/or scalp using the above method. Such conditions include, for example, skin healthiness and dandruff condition of scalp.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: August 19, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Masaru Kosaga, Shan He, TianGui Gong
  • Patent number: 8796024
    Abstract: A method for culturing neural cells using a culture medium is provided. Each neural cell includes a neural cell body and at least one neurite branched from the neural cell body. The culture medium includes a substrate and a carbon nanotube structure located on the substrate. A surface of the carbon nanotube structure is polarized to form a polar surface. The neural cells are cultured on the polar surface to grow neurites along the carbon nanotube wires. The carbon nanotube structure includes a number of carbon nanotube wires spaced apart from each other. A distance between adjacent carbon nanotube wires is greater than or equal to a diameter of the neural cell body.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: August 5, 2014
    Assignees: Tsinghua University, Hon Hai Precision Industry Co., Ltd.
    Inventors: Li Fan, Chen Feng, Wen-Mei Zhao
  • Patent number: 8790929
    Abstract: The invention provides a reagent for diluting a blood sample, comprising water, polyoxyethylene alkyl ether having a hydroxyl value of 52 to 60, and an osmo-regulator for regulating the osmotic pressure of the reagent in the range of 150 to 400 mOsm/kg, as well as a method for measuring the mean corpuscular volume of a blood sample.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: July 29, 2014
    Assignee: Sysmex Corporation
    Inventors: Yusuke Mori, Kinya Uchihashi, Yasuhiro Sakai
  • Patent number: 8778404
    Abstract: The present inventors discovered that the onset of galactosamine hepatopathy is suppressed by nutritional compositions comprising as essential ingredients: whey protein hydrolysates; lecithin and oils and fats high in oleic acid, which are able to improve the lipid metabolism; and palatinose having an insulin-sparing effect. Furthermore, the whey protein hydrolysate included in the nutritional compositions was found to suppress endotoxin-induced TNF-a and interleukin 6 (IL-6) production in macrophages.
    Type: Grant
    Filed: May 30, 2009
    Date of Patent: July 15, 2014
    Assignee: Meiji Co., Ltd.
    Inventors: Hisae Kume, Makoto Yamaguchi, Kenji Mizumoto, Hajime Sasaki
  • Patent number: 8778629
    Abstract: A sterility test method includes: selecting strain and culture medium, preparing bacterial cultures, transcribing fingerprint characteristics in thermograms as indices to verify the characteristics, drawing the thermodynamic parameters of the thermogram, determining the positive judgment index and performing sterility test for the samples. A fully-enclosed bacteria collecting ampoule incubator includes bacteria collecting ampoule system, sample and liquid feeding system and peristalsis liquid discharge system. The sample and liquid feeding system is connected with the bacteria collecting ampoule system by the liquid intake tube; and the bacteria collecting ampoule system is connected with the peristalsis liquid discharge system by the liquid drainage tube. The invention is characterized by short inspection time, high sensitivity, high automation and accurate test results on microbial contamination. It can also provide the overall process curve on the growth conditions.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: July 15, 2014
    Assignee: 302 Military Hospital of China
    Inventors: Dan Yan, Xiaohe Xiao, Ping Zhang, Yongshen Ren, Cheng Jin
  • Patent number: 8771933
    Abstract: This invention provides methods utilizing a microfluidic device that can quickly and accurately discern differences in deformability between individual cells and sets of cells and continuously fractionate populations of cells based on their deformability. This information may be important in disease diagnosis and treatment efficacy monitoring. For example such a device may be able to determine the stage of malarial infection by using red blood cell deformability. Additionally, methods of the invention may be used as a tool to screen drugs that can make cells more flexible in diseases such as sickle cell anemia that causes sickle cell crises. The relatively low manufacturing and operation costs of methods of the invention enable this device to be used in resource-limited settings to diagnose and monitor disease.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: July 8, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Jongyoon Han, Hansen Bow, Patrick Abgrall
  • Patent number: 8771930
    Abstract: Properties such as toxicity of substances may be determined by assaying properties, fates and effects of substances in an ex vivo metabolically active human organ or tissue under normothermic perfusion with a fluid containing a test substance. The data can be used as, for example, part of a submission to a government regulatory organization. Preferred methods use perfused endocrine gland organs or tissues to evaluate hormone or other bodily chemical disruption caused by substances and pre-donation diseased or injured organs or tissues.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: July 8, 2014
    Assignee: Lifeline Scientific, Inc.
    Inventors: Gerald Curtis, John Brassil, David Kravitz
  • Patent number: 8765364
    Abstract: Methods of validating results of assessments of test substances using human-derived tissues and/or organs, particularly tissues and/or organs unsuitable for transplantation, include assessing the suitability of the organ and/or tissue for substance testing, as well as inter-organ variability and use of exogenous and/or endogenous controls.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: July 1, 2014
    Assignee: Lifeline Scientific, Inc.
    Inventors: Gerald Curtis, John Brassil, David Kravitz
  • Patent number: 8758743
    Abstract: A coenzyme Q10-containing composition comprising a coenzyme Q10 and a hydrophilic fatty acid ester of a polyhydric alcohol; a coenzyme Q10-containing composition comprising a coenzyme Q10, a lipophilic fatty acid ester of a polyhydric alcohol and a hydrophilic fatty acid ester of a polyhydric alcohol; and a food or beverage comprising the coenzyme Q10-containing composition as defined above.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: June 24, 2014
    Assignee: Taiyo Kagaku Co., Ltd.
    Inventors: Rumi Yamaguchi, Hiroaki Yamaguchi, Hironobu Nanbu, Lekh Raj Juneja, Nagahiro Yamazaki
  • Patent number: 8758989
    Abstract: A diagnostic test kit for detecting the presence or quantity of an enzyme or enzyme inhibitor is provided. The diagnostic kit utilizes substrate conjugates to facilitate the detection of the enzyme or enzyme inhibitor via direct detection of the substrate and/or a product formed in an enzyme-catalyzed reaction of the substrate. The substrate conjugates include a substrate joined (e.g., covalently bonded, physically adsorbed, etc.) to a reporter. In one embodiment, for example, a peptide, protein, or glycoprotein substrate is joined to a reporter (e.g., dyed latex particle). In this embodiment, the substrate provides a cleavage target for an enzyme. Specifically, upon contacting the substrate conjugate, the enzyme catalyzes a reaction with the substrate and forms a product conjugate that includes the product of the enzyme catalyzed reaction joined to the reporter. The signal exhibited by the reporters may then be used to indicate the presence or quantity of an enzyme or enzyme inhibitor within the test sample.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: June 24, 2014
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventor: Xuedong Song
  • Patent number: 8758992
    Abstract: The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: June 24, 2014
    Assignee: One Way Liver Genomics, S.L.
    Inventors: Jonathan Barr, Azucena Castro Espido, Jose Maria Mato De La Paz, Maria Luz Martinez Chantar
  • Patent number: 8758746
    Abstract: This invention relates to fertilization modulation compounds and process for implementing them.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: June 24, 2014
    Assignees: Universite Joseph Fourier, Centre National de la Recherche Scientifique
    Inventors: Christophe Arnoult, Michel De Waard, Gerard Lambeau
  • Patent number: 8758768
    Abstract: A process is described for the production of an immunostimulant by submerged cultivation of Lentinus edodes in which mycelium from agar plates or a fermentation broth is added to a liquid medium in a shake flask or a bioreactor containing nutrients such as malt extract, yeast extract, peptone and glucose having access to air or to which air is added, and which is kept in constant movement at approx. 28° C. At the proper conditions, there will be an increase in the production of extracellular lentinan, which is shown to be a better immunostimulant than intracellular lentinan. The extracellular product is precipitated from the growth medium by means of methods for the precipitation of microbial polysaccharide.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: June 24, 2014
    Assignee: Glycanova AS
    Inventors: Bjoern Kristiansen, David Waddell
  • Patent number: 8753832
    Abstract: In quickly assaying a blood component interfered by glucose and/or its derivative on the bedside or in a clinic or in assaying the same by a patient in his/her own home, there has been required an assay method wherein the whole blood can be used as a sample as such without resorting to a centrifuge or the like. A method of assaying a blood component to be used for assaying a blood component interfered by glucose and/or its derivative, characterized by comprising bringing the whole blood into contact with a substance capable of converting glucose and/or its derivative into another substance not interfering the assay and, simultaneously or subsequently, separating blood cells; a device to be used in the assay method; and a kit containing this device.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: June 17, 2014
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Yoshihiko Umegae, Reiko Machida, Yayoi Irie, Toshio Tanabe